%0 Journal Article %1 RN49 %A Murphy, B. P. %A Stuart, A. H. %A Wade, D. %A Cotton, S. %A McGorry, P. D. %D 2006 %J Hum Psychopharmacol %K imported public %N 8 %P 511-7 %R 10.1002/hup.807 %T Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study %U http://onlinelibrary.wiley.com/doi/10.1002/hup.807/abstract %V 21 %X OBJECTIVE: Negative symptoms are debilitating and associated with poor role functioning and reduced quality of life. There is a paucity of research on antipsychotic efficacy against the primary negative symptoms, particularly in first-episode psychosis (FEP). We undertook a prospective, open-label pilot trial to investigate the use of amisulpride in the treatment of young people with FEP characterised by primary negative symptoms. METHOD: Twelve male and two female first-episode patients with primary negative symptoms (aged 16-26) were commenced on low-dose amisulpride (mean 250 mg/day) and followed-up over a 6-month period. Primary outcome measures were the Scale for the Assessment of Negative Symptoms (SANS), the Quality of Life Survey (QLS) and their respective subscales. RESULTS: For the 12 completers there was a statistically significant improvement in SANS summary score (p = 0.036), Affective Flattening subscale global score (p = 0.046), QLS total score (p = 0.021), QLS subscales of Instrumental Role (p = 0.018) and Intra-psychic Foundations (p = 0.009) from baseline to week 24. CONCLUSIONS: Amisulpride appears to be associated with less severe negative symptoms and improved quality of life. Generalisabilty of the findings is limited by the small sample size and open-label design of our study, however the positive findings suggest that further controlled trials are warranted.

@article{RN49, abstract = {OBJECTIVE: Negative symptoms are debilitating and associated with poor role functioning and reduced quality of life. There is a paucity of research on antipsychotic efficacy against the primary negative symptoms, particularly in first-episode psychosis (FEP). We undertook a prospective, open-label pilot trial to investigate the use of amisulpride in the treatment of young people with FEP characterised by primary negative symptoms. METHOD: Twelve male and two female first-episode patients with primary negative symptoms (aged 16-26) were commenced on low-dose amisulpride (mean 250 mg/day) and followed-up over a 6-month period. Primary outcome measures were the Scale for the Assessment of Negative Symptoms (SANS), the Quality of Life Survey (QLS) and their respective subscales. RESULTS: For the 12 completers there was a statistically significant improvement in SANS summary score (p = 0.036), Affective Flattening subscale global score (p = 0.046), QLS total score (p = 0.021), QLS subscales of Instrumental Role (p = 0.018) and Intra-psychic Foundations (p = 0.009) from baseline to week 24. CONCLUSIONS: Amisulpride appears to be associated with less severe negative symptoms and improved quality of life. Generalisabilty of the findings is limited by the small sample size and open-label design of our study, however the positive findings suggest that further controlled trials are warranted.}, added-at = {2017-10-14T21:46:53.000+0200}, author = {Murphy, B. P. and Stuart, A. H. and Wade, D. and Cotton, S. and McGorry, P. D.}, biburl = {https://www.bibsonomy.org/bibtex/2552b4cb644ca5a21151de79e76bbf87b/tngominh}, doi = {10.1002/hup.807}, interhash = {1dd8dd1c5ed69a01c4d0e881bfd5736d}, intrahash = {552b4cb644ca5a21151de79e76bbf87b}, issn = {0885-6222 (Print) 0885-6222}, journal = {Hum Psychopharmacol}, keywords = {imported public}, number = 8, pages = {511-7}, timestamp = {2017-10-15T05:54:59.000+0200}, title = {Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study}, type = {Journal Article}, url = {http://onlinelibrary.wiley.com/doi/10.1002/hup.807/abstract}, volume = 21, year = 2006 }